A Phase III Study of Cabozantinib versus Placebo in Patients with Inoperable or Metastatic Pancreatic Neuroendocrine and Carcinoid Tumors

Share
Print

Full Title

Randomized, Double-blinded Phase III Study of Cabozantinib versus Placebo in Patients with Advanced Neuroendocrine Tumors after Progression on Everolimus (CIRB)

Purpose

The purpose of this study is to see if the drug cabozantinib is effective for treating inoperable or metastatic pancreatic neuroendocrine and carcinoid tumors that continue to grow despite everolimus treatment. Cabozantinib is already used to treat thyroid and kidney cancers. It inhibits the development of the blood vessels that tumors need to grow and spread and is taken orally (by mouth). Patients in this study will be randomly assigned to receive either cabozantinib or a placebo.

Eligibility

To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have an inoperable or metastatic pancreatic neuroendocrine or carcinoid tumor that continues to grow despite prior treatment that included everolimus.
  • At least 4 weeks must pass between the completion of previous treatments and entry into the study.
  • Patients must be able to walk and do routine activities for more than half of their normal waking hours.
  • This study is for patients age 18 and older.

For more information and to inquire about eligibility for this study, please contact Dr. Nitya Raj at 646-888-4849.

Protocol

19-265

Phase

III

Disease Status

Relapsed or Refractory

Investigator

Co-Investigators